CCA Industries, Inc (CAWW) Fair Value & Analysis
Consumer Defensive · US · Market cap $3.6M
Fair value as of: Jun 25, 2026
Analysis
CCA Industries, Inc (CAWW) currently trades at $0.4800, while our model-based Fair Value estimate is $0.2800 — implying the stock looks roughly 41.7% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
CCA Industries, Inc. manufactures and distributes health and beauty aid products in the United States and internationally. It offers oral health-care products under the Plus+White brand; skin-care products under the Sudden Change and Porcelana brand names; nail treatments under the brand name of Nutra Nail; medicated topical and shave gels under the Bikini Zone brand; sun care products under Solar Sense brand name; depilatories under the Hair Off brand; brain health supplements under Neutein brand name; perfumes under the brand name of Sunset Cafe. The company markets its products to drug, food, and mass-merchandise retail chains; warehouse clubs; and wholesale beauty-aids through independent sales representatives and distributors, as well as through Internet. CCA Industries, Inc. was incorporated in 1983 and is based in Lyndhurst, New Jersey.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is CCA Industries, Inc (CAWW) undervalued?
What is the fair value of CAWW?
What is the quality score of CAWW?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.